.png)
Now Available at Prodigy Health: Qfitlia (fitusiran)
Qfitlia (fitusiran), Sanofi’s RNA-based treatment for Hemophilia A or B, is now available through Prodigy Health. Approved for patients aged 12 and older, regardless of inhibitor status, this therapy represents a significant advancement in the management of bleeding disorders.
Qfitlia works by lowering antithrombin levels to promote thrombin generation, helping restore balance to the clotting process. Its innovative RNA interference (RNAi) mechanism offers a new approach to routine prophylaxis, on-demand treatment, and perioperative care. Delivered in a convenient, subcutaneous pen, it supports both flexibility and reliability in treatment delivery.
As part of our continued commitment to expanding access to transformative therapies, Prodigy Health is now offering Qfitlia to providers nationwide. With responsive service, deep industry expertise, and efficient distribution, we’re here to support the evolving needs of patients and care teams alike.
To learn more or place an order, please connect with a Prodigy Health representative at 877-693-4376 or visit www.prodigyhealth.com/contact.
